| Biomarker ID | 627 |
| PMID | 21482022 |
| Year | 2011 |
| Biomarker | %fPSA |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Bivariate Model: OR: 0.007 (95% CI: 0.000-0.276) |
| Effect on Pathways | Pathways include:-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Prostate Cancer Vs Controls |
| Type of Biomarker | Diagnostic |
| Cohort | 268 patients were chosen for the study out of which 107 suffered from prostate cancer. |
| Senstivity | 20% (95% CI: 8.5–29.0) |
| Specificity | 90% |
| AUC | 0.60 (95% CI: 0.53–0.66) |
| Accuracy | NA |
| Level Of Significance | p=0.008 |
| Method Used | Access2 Immunoassay System analyzer |
| Clinical | No |
| Remarks | real clinical setting of consecutive men with tPSA 2.0–10 ng/ml and negative digital rectal examination were included. Base Model included all the variables that showed a corrected p value (pc)≤0.25 in comparisons between groups |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |